Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “CANCER,NOS”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT02682693
What this trial is testing

Denosumab as an add-on Neoadjuvant Treatment (GeparX)

Who this might be right for
Breast Cancer Female NOSTubular Breast Cancer Stage IIMucinous Breast Cancer Stage II+4 more
GBG Forschungs GmbH 780
Not applicableActive Not RecruitingNCT01653093
What this trial is testing

3-Tesla MRI in Finding Tumors in Patients With Known or Suspected Prostate Cancer

Who this might be right for
Prostate Cancer
University of Cincinnati 280
Testing effectiveness (Phase 2)UnknownNCT05527821
What this trial is testing

Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors

Who this might be right for
Unresectable Advanced Solid TumorsBiliary Tract Tumors, Gastric Cancer, Small Cell Lung Cancer
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 36
Testing effectiveness (Phase 2)Ended earlyNCT00004221
What this trial is testing

Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

Who this might be right for
Malignant Ovarian Mixed Epithelial TumorOvarian Clear Cell CystadenocarcinomaOvarian Endometrioid Adenocarcinoma+5 more
Gynecologic Oncology Group 12
Not applicableUnknownNCT02997384
What this trial is testing

Feasibility of Breast Cancer Risk Evaluation in Women From the General Population

Who this might be right for
Breastcancer
Gustave Roussy, Cancer Campus, Grand Paris 600
Not applicableStudy completedNCT03363347
What this trial is testing

BRAF V600E and Redifferentiation Therapy in Radioiodine-refractory Papillary Thyroid Cancer

Who this might be right for
Thyroid Cancer
Heidelberg University 25
Not applicableStudy completedNCT02372747
What this trial is testing

Comparison of Delta-Shaped and Billroth II After TLDG

Who this might be right for
Gastric Cancer
The First Hospital of Jilin University 78
Not applicableEnded earlyNCT05062447
What this trial is testing

Adaptive and Maladaptive Emotions in Patients With Cancer: Identification of Indicators

Who this might be right for
Adaptation, Emotional
Amsterdam UMC, location VUmc 134
Testing effectiveness (Phase 2)Study completedNCT00005649
What this trial is testing

Paclitaxel and Capecitabine in Treating Women With Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche
Testing effectiveness (Phase 2)WithdrawnNCT04834349
What this trial is testing

Re-irradiation With NBTXR3 in Combination With Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer

Who this might be right for
Recurrent Head and Neck Squamous Cell CarcinomaUnresectable Head and Neck Squamous Cell Carcinoma
M.D. Anderson Cancer Center
Not applicableUnknownNCT06069648
What this trial is testing

Effects of Decision Aids on the Participation of South Asian Women in Cervical Cancer Screening

Who this might be right for
Cervical Cancer
Chinese University of Hong Kong 270
Not applicableStudy completedNCT04089748
What this trial is testing

Basal Tumours in Bladder Cancer, Response to chemoTherapy

Who this might be right for
Bladder CancerChemotherapy Effect
University Hospital, Rouen 293
Early research (Phase 1)Study completedNCT02646748
What this trial is testing

Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors

Who this might be right for
Colorectal Cancer (CRC)Endometrial CancerMelanoma+8 more
Incyte Corporation 159
Not applicableLooking for participantsNCT06966778
What this trial is testing

Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial

Who this might be right for
Localized Prostate CancerPostoperative Urinary Incontinence
National Taiwan University Hospital 135
Not applicableUnknownNCT04721184
What this trial is testing

Impact of Low Muscle Mass in HNC Treated With Immunotherapy

Who this might be right for
Head and Neck Small Cell CarcinomaSarcopenia
Institut Català d'Oncologia 120
Early research (Phase 1)Study completedNCT01051284
What this trial is testing

Gemcitabine and Cyberknife Radiation Therapy for Pancreatic Cancer

Who this might be right for
Pancreatic Cancer
Georgetown University 14
Early research (Phase 1)Active Not RecruitingNCT03502733
What this trial is testing

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Who this might be right for
LymphomaMetastatic Malignant Solid NeoplasmRecurrent Malignant Solid Neoplasm+1 more
National Cancer Institute (NCI) 64
Not applicableUnknownNCT06471452
What this trial is testing

To Live Better After Breast Cancer Treatment

Who this might be right for
Breast Cancer Survivorship
Karolinska Institutet 40
Testing effectiveness (Phase 2)UnknownNCT05117658
What this trial is testing

Study of HA121-28 in Patients With Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 83
Not applicableLooking for participantsNCT07465848
What this trial is testing

Prospective Multicentre Study for the Application of Telomere Measurement Technology as a Tool for Lung Cancer Diagnosis

Who this might be right for
Lung Cancer (Diagnosis)Health Adult SubjectsPatient
Grupo Español de Investigación en Diagnóstico y Tratamiento Hipertemprano de Enfermedades (GeDiTPhe) 1,200
Next Page